Investigation of Danazol as a contraceptive agent
Danazol, the 2,3-isoxasol derivative of 17 α-ethinyl testosterone, was administered to 17 healthy volunteers during the first 7 days of the menstrual cycle, to see if an inadequate luteal phase would result. The follicular span was lengthened, and FSH levels either did not increase or were lowered d...
Gespeichert in:
| Veröffentlicht in: | Contraception (Stoneham) 1976-05, Vol.13 (5), p.619-630 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 630 |
|---|---|
| container_issue | 5 |
| container_start_page | 619 |
| container_title | Contraception (Stoneham) |
| container_volume | 13 |
| creator | Wentz, Anne Colston Jones, Georgeanna Seegar Sapp, Karan C. |
| description | Danazol, the 2,3-isoxasol derivative of 17
α-ethinyl testosterone, was administered to 17 healthy volunteers during the first 7 days of the menstrual cycle, to see if an inadequate luteal phase would result. The follicular span was lengthened, and FSH levels either did not increase or were lowered during Danazol dosage in most women. Although delayed, the LH surge was normal, and a normal progesterone output was documented during the luteal phase. Thus, an inadequate luteal phase was not induced by inhibition of FSH-stimulated follicular development. |
| doi_str_mv | 10.1016/0010-7824(76)90017-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83374579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0010782476900172</els_id><sourcerecordid>83374579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-af87c5d61198f1a8ab4852df9815e725bf0322e0b13f3ca9ca1e9b29403d802e3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotVbfQGFWoovRXCaTZCOUeisU3Og6ZDInJTKd1GRa0Kd36hTdCQcOh_8_tw-hc4JvCCblLcYE50LS4kqU16qvRE4P0JhIoXLMiTxE41_LMTpJ6R1jLBQXIzQitOyjGCMyb7eQOr80nQ9tFlx2b1rzFZrMpMxkNrRdNBbWnd9CZpbQdqfoyJkmwdk-T9Db48Pr7DlfvDzNZ9NFbhkXXW6cFJbXJSFKOmKkqQrJae2UJBwE5ZXDjFLAFWGOWaOsIaAqqgrMaokpsAm6HOauY_jY9DfqlU8Wmsa0EDZJS8ZEwYXqjcVgtDGkFMHpdfQrEz81wXpHSu8w6B0GLUr9Q0rTvu1iP39TraD-axrQ9PrdoEP_5NZD1Ml6aC3UPoLtdB38_wu-AfnFdlI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83374579</pqid></control><display><type>article</type><title>Investigation of Danazol as a contraceptive agent</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wentz, Anne Colston ; Jones, Georgeanna Seegar ; Sapp, Karan C.</creator><creatorcontrib>Wentz, Anne Colston ; Jones, Georgeanna Seegar ; Sapp, Karan C.</creatorcontrib><description>Danazol, the 2,3-isoxasol derivative of 17
α-ethinyl testosterone, was administered to 17 healthy volunteers during the first 7 days of the menstrual cycle, to see if an inadequate luteal phase would result. The follicular span was lengthened, and FSH levels either did not increase or were lowered during Danazol dosage in most women. Although delayed, the LH surge was normal, and a normal progesterone output was documented during the luteal phase. Thus, an inadequate luteal phase was not induced by inhibition of FSH-stimulated follicular development.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/0010-7824(76)90017-2</identifier><identifier>PMID: 1261264</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Body Temperature ; Contraceptive Agents, Female ; Corpus Luteum - drug effects ; Danazol - pharmacology ; Drug Evaluation ; Estradiol - blood ; Female ; Follicle Stimulating Hormone - blood ; Humans ; Luteal Phase - drug effects ; Luteinizing Hormone - blood ; Menstruation - drug effects ; Population ; Pregnadienes - pharmacology ; Progesterone - blood ; Reproduction and population</subject><ispartof>Contraception (Stoneham), 1976-05, Vol.13 (5), p.619-630</ispartof><rights>1976</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-af87c5d61198f1a8ab4852df9815e725bf0322e0b13f3ca9ca1e9b29403d802e3</citedby><cites>FETCH-LOGICAL-c357t-af87c5d61198f1a8ab4852df9815e725bf0322e0b13f3ca9ca1e9b29403d802e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0010782476900172$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1261264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wentz, Anne Colston</creatorcontrib><creatorcontrib>Jones, Georgeanna Seegar</creatorcontrib><creatorcontrib>Sapp, Karan C.</creatorcontrib><title>Investigation of Danazol as a contraceptive agent</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>Danazol, the 2,3-isoxasol derivative of 17
α-ethinyl testosterone, was administered to 17 healthy volunteers during the first 7 days of the menstrual cycle, to see if an inadequate luteal phase would result. The follicular span was lengthened, and FSH levels either did not increase or were lowered during Danazol dosage in most women. Although delayed, the LH surge was normal, and a normal progesterone output was documented during the luteal phase. Thus, an inadequate luteal phase was not induced by inhibition of FSH-stimulated follicular development.</description><subject>Body Temperature</subject><subject>Contraceptive Agents, Female</subject><subject>Corpus Luteum - drug effects</subject><subject>Danazol - pharmacology</subject><subject>Drug Evaluation</subject><subject>Estradiol - blood</subject><subject>Female</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Humans</subject><subject>Luteal Phase - drug effects</subject><subject>Luteinizing Hormone - blood</subject><subject>Menstruation - drug effects</subject><subject>Population</subject><subject>Pregnadienes - pharmacology</subject><subject>Progesterone - blood</subject><subject>Reproduction and population</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotVbfQGFWoovRXCaTZCOUeisU3Og6ZDInJTKd1GRa0Kd36hTdCQcOh_8_tw-hc4JvCCblLcYE50LS4kqU16qvRE4P0JhIoXLMiTxE41_LMTpJ6R1jLBQXIzQitOyjGCMyb7eQOr80nQ9tFlx2b1rzFZrMpMxkNrRdNBbWnd9CZpbQdqfoyJkmwdk-T9Db48Pr7DlfvDzNZ9NFbhkXXW6cFJbXJSFKOmKkqQrJae2UJBwE5ZXDjFLAFWGOWaOsIaAqqgrMaokpsAm6HOauY_jY9DfqlU8Wmsa0EDZJS8ZEwYXqjcVgtDGkFMHpdfQrEz81wXpHSu8w6B0GLUr9Q0rTvu1iP39TraD-axrQ9PrdoEP_5NZD1Ml6aC3UPoLtdB38_wu-AfnFdlI</recordid><startdate>197605</startdate><enddate>197605</enddate><creator>Wentz, Anne Colston</creator><creator>Jones, Georgeanna Seegar</creator><creator>Sapp, Karan C.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197605</creationdate><title>Investigation of Danazol as a contraceptive agent</title><author>Wentz, Anne Colston ; Jones, Georgeanna Seegar ; Sapp, Karan C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-af87c5d61198f1a8ab4852df9815e725bf0322e0b13f3ca9ca1e9b29403d802e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Body Temperature</topic><topic>Contraceptive Agents, Female</topic><topic>Corpus Luteum - drug effects</topic><topic>Danazol - pharmacology</topic><topic>Drug Evaluation</topic><topic>Estradiol - blood</topic><topic>Female</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Humans</topic><topic>Luteal Phase - drug effects</topic><topic>Luteinizing Hormone - blood</topic><topic>Menstruation - drug effects</topic><topic>Population</topic><topic>Pregnadienes - pharmacology</topic><topic>Progesterone - blood</topic><topic>Reproduction and population</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wentz, Anne Colston</creatorcontrib><creatorcontrib>Jones, Georgeanna Seegar</creatorcontrib><creatorcontrib>Sapp, Karan C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wentz, Anne Colston</au><au>Jones, Georgeanna Seegar</au><au>Sapp, Karan C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of Danazol as a contraceptive agent</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>1976-05</date><risdate>1976</risdate><volume>13</volume><issue>5</issue><spage>619</spage><epage>630</epage><pages>619-630</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><abstract>Danazol, the 2,3-isoxasol derivative of 17
α-ethinyl testosterone, was administered to 17 healthy volunteers during the first 7 days of the menstrual cycle, to see if an inadequate luteal phase would result. The follicular span was lengthened, and FSH levels either did not increase or were lowered during Danazol dosage in most women. Although delayed, the LH surge was normal, and a normal progesterone output was documented during the luteal phase. Thus, an inadequate luteal phase was not induced by inhibition of FSH-stimulated follicular development.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1261264</pmid><doi>10.1016/0010-7824(76)90017-2</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0010-7824 |
| ispartof | Contraception (Stoneham), 1976-05, Vol.13 (5), p.619-630 |
| issn | 0010-7824 1879-0518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_83374579 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Body Temperature Contraceptive Agents, Female Corpus Luteum - drug effects Danazol - pharmacology Drug Evaluation Estradiol - blood Female Follicle Stimulating Hormone - blood Humans Luteal Phase - drug effects Luteinizing Hormone - blood Menstruation - drug effects Population Pregnadienes - pharmacology Progesterone - blood Reproduction and population |
| title | Investigation of Danazol as a contraceptive agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20Danazol%20as%20a%20contraceptive%20agent&rft.jtitle=Contraception%20(Stoneham)&rft.au=Wentz,%20Anne%20Colston&rft.date=1976-05&rft.volume=13&rft.issue=5&rft.spage=619&rft.epage=630&rft.pages=619-630&rft.issn=0010-7824&rft.eissn=1879-0518&rft_id=info:doi/10.1016/0010-7824(76)90017-2&rft_dat=%3Cproquest_cross%3E83374579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83374579&rft_id=info:pmid/1261264&rft_els_id=0010782476900172&rfr_iscdi=true |